<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/73A127C7-B76B-4D89-9C46-4578A933FDBE"><gtr:id>73A127C7-B76B-4D89-9C46-4578A933FDBE</gtr:id><gtr:name>Novavax AB</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>The Jenner Institute</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/73A127C7-B76B-4D89-9C46-4578A933FDBE"><gtr:id>73A127C7-B76B-4D89-9C46-4578A933FDBE</gtr:id><gtr:name>Novavax AB</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ008680%2F1"><gtr:id>908D138A-7614-47DB-B7B3-BEF0B1DED2D5</gtr:id><gtr:title>MICA: Developmental Clinical Sciences - Clinical Evaluation of a Sporozoite and Liver-Stage Combination Malaria Vaccine against Plasmodium falciparum</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J008680/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2016-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-12-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>916661</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novavax AB</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Novavax collaboration</gtr:description><gtr:id>64B76D62-321F-4760-8BA5-2217C82E68F2</gtr:id><gtr:impact>Five clinical trials have been undertaken with their adjuvant by my team. We have also produced a lot of pre-clinical data</gtr:impact><gtr:outcomeId>58c99555c1bec6.67389228-1</gtr:outcomeId><gtr:partnerContribution>Novavax provide their adjuvant and we pay them for this material</gtr:partnerContribution><gtr:piContribution>Novavax provide an adjuvant, matrix-M for our malaria vaccine development programme and we generate malaria vaccines.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translation Award</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>BB14E21A-3268-4A07-BB9D-B60A05673826</gtr:id><gtr:outcomeId>58c993f27d90e4.94496525</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is a new malaria vaccine candidate that targets the sporozoite stage of the parasite life cycle. It has shown excellent pre-clinical safety, immunogenicity and efficacy. Recruitment into this clinical trial is largely complete as of early March 2016</gtr:description><gtr:id>6D9A1630-5A29-465D-81DC-887EA5477C4C</gtr:id><gtr:impact>This product is in a phase I clinical trial. A phase IIa clinical trial is being planned.</gtr:impact><gtr:outcomeId>apJnhn3Am9M</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>R21 particle vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://www.jenner.ac.uk</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is a new malaria vaccine based on a multimerised fusion protein of part of the P. falciparum circumsporozoite protein fused to hepatitis B surface antigen.</gtr:description><gtr:id>6B0A1951-C506-4229-AB1A-E689FF9603CB</gtr:id><gtr:impact>We have recently completed a first test of the efficacy of this vaccine in the matrix-M adjuvant from Novavax. The vaccine was safe, very immunogenic and the efficacy results against a controlled human malaria infection are very encouraging. We plan further development of this candidate vaccine with funding support from Wellcome, the European Commission and others.</gtr:impact><gtr:outcomeId>58c997975ab3e8.03734863</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>R21 malaria vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A process for manufacture of a malaria protein particle to GMP standard has been developed. This now involves use of an innovative C-tag immunoaffinity purification technology.</gtr:description><gtr:id>45BAC762-5375-4CD1-AD7E-E9687DB2AC1B</gtr:id><gtr:impact>This will allow a clinical trial of the vaccine that is being manufactured in 2015.</gtr:impact><gtr:outcomeId>NoNow7NBMQq</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GMP process</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.jenner.ac.uk</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F3BF9FFC-55CA-404C-82D8-D1A3F601B30E</gtr:id><gtr:title>Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/323892afeb5a10953c87de8214072d27"><gtr:id>323892afeb5a10953c87de8214072d27</gtr:id><gtr:otherNames>Collins KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa946e7456308.60579486</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J008680/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>